CHMP recommends Sirturo for Tuberculosis-Jansen Cilag
The CHMP has recommended conditional marketing for the novel treatment for Tuberculosis, Sirturo (bedaquiline 100mg tablets) from Janssen Cilag (Johnson & Johnson).
The intended indication is for use as part of an appropriate combination regimen for pulmonary multidrug-resistant Tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins